Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Arterial Hypertension

In brief

The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in this population and to test the hypothesis that 6 months treatment with nilotinib will significantly reduce pulmonary artery resistance.

Key facts

Study ID

NCT01179737

Run by

Novartis Pharmaceuticals

People needed

23

Starts

2010-07-01

Expected to finish

2013-01-01

Last updated by the study team

2014-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• World Health Organization (WHO) Functional Class II or III
• 6MWD ≥ 150 m and ≤ 450 m at screening
• Current diagnosis of PAH according to Dana Point 2008 Meeting
• Inadequate clinical response on one or more class(es) of PAH drug
• Stabilization of pulmonary hypertension medications for ≥ 2 months on approved therapeutic dose of at least one PAH drug and still symptomatic with WHO functional Class II or III performance.

You may not qualify if…

• Women of child-bearing potential not practicing birth control
• In treatment with chronic nitric oxide therapy
• Pre-existing lung disease
• Use of drugs prolonging the QT interval or strong CYP3A4 inhibitors
• Long QT syndrome or QTc > 450 ms males; > 470 ms females.
• WHO Class IV
• Pulmonary capillary wedge pressure > 15 mm Hg
• Other diagnosis of PAH in WHO Diagnostic Group 1
• PAH associated with: venous hypertension (WHO Diagnostic Group II), hypoxia (WHO Diagnostic Group III), chronic pulmonary thromboembolic disease (WHO Diagnostic Group IV) or other miscellaneous causes (WHO Diagnostic Class V, which includes sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels)
• Thrombocytopenia < 50 x109/L (50 x 103/µL)
• Uncontrolled systemic arterial hypertension, systolic > 160 mm Hg or diastolic >90 mm Hg
• Any advanced, severe, or unstable disease of any type that may interfere with the primary and secondary endpoint evaluations.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Boston, Massachusetts, United States
• Novartis Investigative Site — Ann Arbor, Michigan, United States
• Novartis Investigative Site — Chapel Hill, North Carolina, United States
• Novartis Investigative Site — Cleveland, Ohio, United States
• Novartis Investigative Site — Nashville, Tennessee, United States
• Novartis Investigative Site — Calgary, Alberta, Canada
• Novartis Investigative Site — Hamburg, Germany
• Novartis Investigative Site — Heidelberg, Germany
• Novartis Investigative Site — Marburg, Germany
• Novartis Investigative Site — Singapore, Singapore, Singapore
• Novartis Investigative Site — Singapore, Singapore, Singapore
• Novartis Investigative Site — Seoul, Korea, South Korea
• Novartis Investigative Site — Zurich, Switzerland, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.